Prospective assessment of reactogenicity and disease activity after recombinant zoster vaccination in Japanese patients with inflammatory bowel disease.

What To Know

This brief reports a prospective observational study from Japan that tracked safety and short-term disease activity after two doses of recombinant zoster vaccine (RZV) in 48 adults with inflammatory bowel disease, most of whom had ulcerative colitis.

Patients kept diaries to record local and systemic reactions for 7 days after vaccination and other adverse events for 30 days; serious adverse events were monitored for 6 months.

The study found that solicited (expected) local and systemic reactions were common but non-serious; no serious adverse events, hospitalizations, treatment escalations, or clinical flares were observed during the short follow-up.

In the subgroup with ulcerative colitis, patient-reported PRO2 scores did not show apparent worsening over 8 weeks after vaccination. Because only four people with Crohn's disease were included, the findings primarily apply to patients with ulcerative colitis and cannot support firm conclusions about RZV safety in Crohn's disease.

This summary is grounded in the study abstract provided on PubMed and does not reflect review of full journal text beyond that abstract.